Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer targeting the molecular differences. Blueprint Medicines focuses selective drugs for genomically defined cancer patients.
Website: blueprintmedicines.com


  • Good financial results growth rate 27.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (31.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -2.0% (LTM)
  • Share price is 194.5% higher than minimum and 0.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: BPMC
Share price, USD:  (0.0%)129.46
year average price 129.37  


year start price 127.96 2025-06-13

min close price 127.96 2025-06-13

max close price 129.46 2025-07-17

current price 129.46 2026-06-12
Common stocks: 59 570 497

Dividend Yield:  0.0%
EV / Sales: 13.6x
Margin (EBITDA LTM / Revenue): -27.8%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 7 712
Net Debt ($m): -110
EV (Enterprise Value): 7 602
EBITDA LTM (млн $): -156
Price to Book: 22.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-15businesswire.com

Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

2025-08-27businesswire.com

Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

2025-07-14globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)

2025-06-12prnewswire.com

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

2025-06-02globenewswire.com

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

2025-06-02barrons.com

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

2025-05-01seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

2025-04-07seekingalpha.com

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

2025-02-14zacks.com

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

2025-02-13seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 149M 509M 128M 138M 96M 249M 57M 58M 63M 204M 66M 180M 794M
costOfRevenue 3M 20M 2M 11M 8M 13M 5M 2M 3M 18M 3M 18M 425 000
grossProfit 147M 489M 126M 127M 88M 237M 52M 55M 60M 186M 63M 162M 793M
grossProfitRatio 0.981 0.985 0.919 0.917 0.92 0.96 0.95 0.955
researchAndDevelopmentExpenses 92M 341M 85M 81M 83M 428M 110M 110M 112M 477M 128M 601M 327M
generalAndAdministrativeExpenses 0 263M 63M 67M 67M 278M 58M 53M 0 219M 0 182M 148M
sellingAndMarketingExpenses 0 97M 27M 23M 17M 17M 13M 19M 0 18M 0 14M 9M
sellingGeneralAndAdministrativeExpenses 96M 359M 90M 89M 84M 295M 71M 72M 71M 237M 58M 195M 158M
otherExpenses 0 0 0 -1000 376 000 0 -728 000 -626 000 1M 9M 2M 8M -366 000
operatingExpenses 188M 701M 175M 170M 167M 723M 181M 183M 184M 724M 187M 804M 485M
costAndExpenses 190M 721M 177M 181M 175M 736M 186M 186M 187M 742M 190M 822M 485M
interestIncome 0 41M 11M 10M 9M 33M 9M 8M 0 0 0 2M 7M
interestExpense 8M 69M 19M 17M 15M 52M -4M -4M 6M 17M -8M 0 0
depreciationAndAmortization -34M 16M 4M 4M 5M 12M 3M 4M 12M 20M 2M 13M 12M
ebitda -41M 19M -33M -29M -74M -470M -129M -128M -123M -515M -123M -628M 309M
ebitdaratio -0.275 -0.26 -0.285 -0.77 -2.28 -2.223 -1.947 -1.859
operatingIncome -41M -212M -49M -43M -79M -486M -129M -128M -135M -549M -124M -648M 302M
operatingIncomeRatio -0.275 -0.382 -0.312 -0.82 -2.28 -2.223 -2.139 -1.884
totalOtherIncomeExpensesNet 42M 146M -7M -7M 168M -20M -5M -626 000 6M -15M -8M 897 000 6M
incomeBeforeTax 1M -66M -56M -50M 89M -506M -134M -133M -129M -552M -132M -641M 315M
incomeBeforeTaxRatio 0.009 -0.437 -0.361 0.929 -2.36 -2.303 -2.039 -2.005
incomeTaxExpense 789 000 1M 273 000 102 000 180 000 968 000 197 000 190 000 520 000 5M 886 000 3M 1M
netIncome 496 000 -67M -56M -50M 89M -507M -134M -133M -130M -558M -133M -644M 314M
netIncomeRatio 0.003 -0.439 -0.362 0.927 -2.364 -2.307 -2.047 -2.018
eps 0.01 -1.07 -0.89 -0.8 1.45 -8.37 -2.2 -2.19 -2.15 -9.35 -2.23 -11.01 5.76
epsdiluted 0.01 -0.89 -0.8 1.4 -2.2 -2.19 -2.15 -2.23
weightedAverageShsOut 64M 63M 63M 63M 62M 61M 61M 61M 60M 60M 60M 59M 55M
weightedAverageShsOutDil 64M 63M 63M 63M 64M 61M 61M 61M 60M 60M 60M 59M 56M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -28M -19M -17M 2M 7M
ebit 3M -482M -529M -641M 315M
nonOperatingIncomeExcludingInterest -215M -4M -9M -897 000 -6M
netIncomeFromContinuingOperations -67M -507M -558M -644M 314M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -67M -507M -558M -644M 314M
epsDiluted -1.07 -8.37 -9.35 -11.01 5.59

Balance Sheet Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 122M 102M 89M 55M 113M 71M 56M 76M 170M 120M 291M 210M 685M
shortTermInvestments 454M 513M 645M 709M 535M 639M 657M 647M 652M 825M 846M 267M 187M
cashAndShortTermInvestments 576M 615M 734M 764M 648M 711M 827M 837M 961M 1 078M 1 137M 1 035M 1 550M
netReceivables 80M 78M 66M 85M 60M 43M 41M 38M 31M 37M 22M 37M 25M
inventory 13M 14M 13M 15M 31M 21M 16M 17M 18M 30M 35M 22M 9M
otherCurrentAssets 33M 36M 42M 40M 38M 33M 37M 33M 731M 35M 34M 0 0
totalCurrentAssets 702M 743M 855M 904M 777M 808M 808M 811M 900M 1 047M 1 228M 554M 928M
propertyPlantEquipmentNet 98M 101M 104M 109M 113M 116M 116M 114M 113M 115M 117M 121M 102M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 277M 0 143M 126M 84M 142M 142M 167M 161M 83M 558M 678M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 396M 59M 241M 48M 23M 41M 39M 39M 40M 27M 30M 20M 11M
totalNonCurrentAssets 494M 437M 345M 300M 262M 241M 297M 295M 320M 303M 231M 698M 791M
otherAssets 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 1 196M 1 180M 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M 1 252M 1 718M
accountPayables 800 000 7M 5M 5M 5M 5M 7M 7M 11M 3M 4M 8M 4M
shortTermDebt 58M 44M 58M 127M 87M 69M 42M 29M 28M 17M 25M 8M 8M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 64M 64M 4M 7M 812 000 448M 446M 443M 449M 25M 37M 13M
otherCurrentLiabilities 190M 80M 131M 108M 107M 61M -300M -313M -309M 31M 121M 85M 70M
totalCurrentLiabilities 251M 261M 258M 244M 207M 215M 197M 169M 173M 183M 176M 150M 131M
longTermDebt 65M 343M 413M 626M 432M 611M 84M 87M 90M 122M 219M 0 0
deferredRevenueNonCurrent 0 202M 8M 8M 5M 5M 5M 5M 5M 427M 415M 25M 41M
deferredTaxLiabilitiesNonCurrent 0 0 0 75M 78M 0 0 0 0 0 0 0 -13M
otherNonCurrentLiabilities 538M 7M 207M 6M 6M 6M 616M 534M 538M 437M 588M 3M 7M
totalNonCurrentLiabilities 603M 620M 629M 640M 521M 704M 705M 626M 633M 652M 643M 132M 118M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 82M 85M 88M 78M 94M 96M 98M 101M 103M 106M 111M 90M
totalLiabilities 853M 881M 887M 883M 728M 919M 903M 795M 806M 835M 818M 281M 248M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 65 000 64 000 63 000 63 000 63 000 61 000 61 000 61 000 60 000 60 000 60 000 59 000 58 000
retainedEarnings -2 407M -2 407M -2 357M -2 301M -2 251M -2 340M -2 229M -2 095M -1 963M -1 833M -1 674M -1 275M -631M
accumulatedOtherComprehensiveIncomeLoss -3M -4M -1M -4M -4M -3M -3M -4M -5M -10M -15M -4M -5M
othertotalStockholdersEquity 2 752M 2 671M 2 625M 2 565M 2 434M 2 411M 2 381M 2 329M
totalStockholdersEquity 342M 299M 313M 320M 311M 131M 203M 311M 414M 515M 640M 971M 1 470M
totalEquity 342M 299M 313M 320M 311M 131M 203M 311M 414M 515M 640M 971M 1 470M
totalLiabilitiesAndStockholdersEquity 1 196M 1 200M 1 204M 1 038M 1 105M 1 106M 1 220M 1 458M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 196M 1 180M 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M 1 252M 1 718M
totalInvestments 454M 791M 645M 852M 661M 724M 657M 647M 652M 959M 929M 825M 865M
totalDebt 123M 469M 471M 740M 598M 774M 126M 116M 118M 242M 244M 111M 90M
netDebt 504 000 367M 382M 686M 485M 703M 70M 41M -52M 123M -47M -99M -595M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 76M 43M 24M 25M 7M
otherReceivables 2M 351 000 13M 12M 18M
prepaids 0 0 0 18M 22M
totalPayables 7M 5M 3M 8M 4M
otherPayables 0 0 0 0 0
accruedExpenses 54M 67M 122M 29M 28M
capitalLeaseObligationsCurrent 13M 12M 11M 8M 8M
capitalLeaseObligationsNonCurrent 69M 82M 93M 103M 82M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 709M 2 474M 2 358M 2 250M 2 107M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 496 000 -67M -56M -50M 89M -507M -134M -133M -130M -558M -133M -644M 314M
depreciationAndAmortization 1M 16M 4M 4M 5M 12M 3M 4M 4M 12M 2M 6M 7M
deferredIncomeTax 0 0 0 0 0 0 -12M 0 0 0 0 1M 466 000
stockBasedCompensation 29M 109M 28M 28M 24M 93M 23M 24M 23M 99M 24M 92M 76M
changeInWorkingCapital 0 0 15M -27M -43M -41M 3M -28M -26M -54M -6M -24M -16M
accountsReceivables -1M -33M 20M -25M -17M -8M -6M -8M -5M 2M 8M -18M -6M
inventory 187 000 -4M -4M -5M 3M -4M 3M -8M 78 000 -9M -6M -13M -7M
accountsPayables -6M 2M 3M -82 000 313 000 2M 26 000 -4M 8M -6M -9M 4M -791 000
otherWorkingCapital 0 0 -4M 3M -29M -31M 6M -8M -29M -41M 1M 3M -2M
otherNonCashItems -85M -251M -5M -3M -128M 7M 12M 3M 6M -2M -17M 270M 6M
netCashProvidedByOperatingActivities -54M -193M -14M -48M -102M -437M -104M -130M -123M -502M -130M -299M 387M
investmentsInPropertyPlantAndEquipment -2M -5M -25 000 -3M -1M -16M -6M -3M -3M -9M -4M -261M -3M
acquisitionsNet 0 0 0 0 0 0 3M 0 0 0 0 258M 431M
purchasesOfInvestments -283M -966M -201M -355M -200M -766M -241M -275M -133M -490M -219M -655M -969M
salesMaturitiesOfInvestments 350M 924M 231M 170M 278M 1 056M 238M 310M 308M 349M 91M 691M 538M
otherInvestingActivites 0 0 0 78M -3M 0 0 -289 000
netCashUsedForInvestingActivites 65M 30M -188M 77M -10M 32M 173M -132M
debtRepayment 0 0 147M -369 000 -98M 0 0 0
commonStockIssued 0 -99M 31M 67M 431 000 5M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 9M 18M 31M -369 000 196M 0 0 381M
netCashUsedProvidedByFinancingActivities 9M 18M 178M 67M 98M 5M 0 381M
effectOfForexChangesOnCash 661 000 -909 000 591 000 -31 000 -145 000 202 000 -541 000 59 000 197 000 -207 000 -379 000 -888 000 -345 000
netChangeInCash 20M 32M 46M -59M 42M -43M -16M -93M 50M -90M 118M -475M 570M
cashAtEndOfPeriod 134M 114M 101M 55M 113M 82M 66M 82M 175M 125M 297M 215M 690M
cashAtBeginningOfPeriod 114M 82M 55M 113M 71M 125M 82M 175M 125M 215M 179M 690M 120M
operatingCashFlow -54M -193M -14M -48M -102M -437M -104M -130M -123M -502M -130M -299M 387M
capitalExpenditure -2M -5M -25 000 -3M -1M -16M -6M -3M -3M -9M -4M -261M -3M
freeCashFlow -56M -197M -14M -51M -103M -453M -111M -133M -126M -511M -134M -560M 384M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -290 000 -258M -431M
netCashProvidedByInvestingActivities -48M 274M -150M -226M -434M
netDebtIssuance 147M 98M 138M 0 0
longTermNetDebtIssuance 147M 98M 138M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 49M 21M 0 0 582M
netCommonStockIssuance 49M 21M 0 0 582M
commonStockIssuance 49M 0 8M 51M 582M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 77M -44 000 424M 51M 35M
netCashProvidedByFinancingActivities 273M 119M 562M 51M 618M
incomeTaxesPaid 1M 0 7M 694 000 778 000
interestPaid 0 38M 10M 0 0

Earning call transcript

2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-30 11:00 ET
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-10-16 12:00 ET
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
2024-09-10 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2024-08-01 11:00 ET
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-07-18 12:00 ET
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
2024-05-30 22:01 ET
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
2024-05-23 21:05 ET
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
2024-05-06 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-02 11:00 ET
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-04-18 12:00 ET
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-11 12:00 ET
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
2024-04-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-23 13:00 ET
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
2024-02-15 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
2024-02-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
2024-01-08 13:00 ET
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 13:00 ET
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 13:05 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
2023-12-09 17:30 ET
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
2023-12-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-28 13:00 ET
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
2023-11-10 13:00 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
2023-11-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-26 11:00 ET
Blueprint Medicines Reports Third Quarter 2023 Results
2023-10-12 12:00 ET
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
2023-10-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-04 20:16 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-02 11:00 ET
Blueprint Medicines Reports Second Quarter 2023 Results
2023-07-19 12:00 ET
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
2023-07-05 20:30 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-05 21:00 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-03 13:00 ET
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
2023-05-23 14:00 ET
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
2023-05-22 20:04 ET
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
2023-05-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 11:00 ET
Blueprint Medicines Reports First Quarter 2023 Results
2023-04-26 14:00 ET
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
2023-04-20 20:01 ET
Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
2023-04-11 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2023-04-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-28 20:05 ET
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
2023-03-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-26 20:00 ET
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
2023-02-23 13:00 ET
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
2023-02-16 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
2023-02-10 13:00 ET
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
2023-02-09 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
2023-02-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-03 14:00 ET
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
2023-01-23 13:00 ET
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
2023-01-06 14:00 ET
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
2023-01-05 13:00 ET
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
2023-01-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-11 22:30 ET
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
2022-12-05 22:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-22 21:36 ET
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
2022-11-09 21:01 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2022-11-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 13:00 ET
Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting
2022-11-01 12:00 ET
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
2022-10-19 12:00 ET
Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022
2022-10-06 20:30 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-06 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-24 12:00 ET
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
2022-08-17 11:00 ET
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
2022-08-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-08-02 11:00 ET
Blueprint Medicines Reports Second Quarter 2022 Results
2022-07-26 12:00 ET
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
2022-07-14 20:15 ET
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
2022-07-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-06-30 11:30 ET
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
2022-06-30 11:15 ET
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
2022-06-23 20:26 ET
Blueprint Medicines Appoints Habib Dable to its Board of Directors
2022-06-09 11:00 ET
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
2022-06-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-05-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-05-03 11:00 ET
Blueprint Medicines Reports First Quarter 2022 Results
2022-04-26 12:00 ET
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
2022-04-08 17:00 ET
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
2022-04-06 20:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-03-25 14:15 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
2022-03-08 21:30 ET
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
2022-03-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-02-28 13:00 ET
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
2022-02-16 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
2022-02-11 21:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2022-02-09 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
2022-02-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-01-28 13:00 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
2022-01-20 13:00 ET
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
2022-01-10 13:00 ET
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
2022-01-06 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-01-05 13:00 ET
Blueprint Medicines Announces CEO and Leadership Transition Plan
2021-12-30 13:51 ET
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
2021-12-09 21:01 ET
Blueprint Medicines Appoints Daniella Beckman to its Board of Directors
2021-12-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-12-06 21:01 ET
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
2021-11-29 12:00 ET
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
2021-11-09 13:00 ET
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
2021-11-09 13:00 ET
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
2021-11-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-10-28 11:00 ET
Blueprint Medicines Reports Third Quarter 2021 Financial Results
2021-10-21 12:00 ET
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
2021-10-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-02 12:00 ET
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-07-29 11:00 ET
Blueprint Medicines Reports Second Quarter 2021 Financial Results
2021-07-28 12:00 ET
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
2021-07-22 12:00 ET
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
2021-07-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-06-16 19:50 ET
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
2021-06-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-05-25 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2021-05-19 21:00 ET
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
2021-05-17 12:00 ET
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
2021-05-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-04-29 11:00 ET
Blueprint Medicines Reports First Quarter 2021 Financial Results
2021-04-22 12:00 ET
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
2021-04-11 18:00 ET
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
2021-04-10 12:30 ET
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
2021-04-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-04-05 12:00 ET
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
2021-03-10 21:30 ET
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
2021-03-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-03-03 13:00 ET
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
2021-02-17 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-10 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
2021-02-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-01-11 13:05 ET
Blueprint Medicines Announces R&D Leadership Transitions
2021-01-11 13:00 ET
Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership
2021-01-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-12-17 13:00 ET
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
2020-12-07 13:00 ET
Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
2020-12-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-12-01 20:15 ET
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
2020-11-23 13:00 ET
Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition
2020-11-03 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-10-29 11:00 ET
Blueprint Medicines Reports Third Quarter 2020 Financial Results
2020-10-22 12:00 ET
Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
2020-10-02 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-09-25 15:46 ET
Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
2020-09-22 11:00 ET
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
2020-09-20 12:25 ET
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer
2020-09-17 12:00 ET
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
2020-09-09 20:01 ET
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
2020-09-04 23:00 ET
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
2020-09-04 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-09-01 12:00 ET
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
2020-08-19 01:27 ET
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
2020-08-04 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-07-30 11:00 ET
Blueprint Medicines Reports Second Quarter 2020 Financial Results
2020-07-24 12:30 ET
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
2020-07-23 12:00 ET
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
2020-07-14 05:00 ET
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
2020-07-02 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-07-01 12:00 ET
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
2020-06-29 22:30 ET
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
2020-06-06 13:00 ET
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
2020-06-03 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-05-29 12:00 ET
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
2020-05-27 20:30 ET
Blueprint Medicines to Present at Upcoming Investors Conferences
2020-05-26 12:00 ET
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
2020-05-15 12:00 ET
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2020-05-14 13:00 ET
Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
2020-05-06 11:00 ET
Blueprint Medicines Reports First Quarter 2020 Financial Results
2020-04-29 12:00 ET
Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020
2020-04-28 11:00 ET
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
2020-04-01 12:00 ET
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
2020-03-16 11:00 ET
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis
2020-03-09 13:00 ET
Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020
2020-02-24 21:05 ET
Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting
2020-02-19 13:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2020-02-13 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-06 21:05 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
2020-02-06 13:00 ET
Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
2020-01-23 03:24 ET
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
2020-01-21 21:01 ET
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
2020-01-08 13:00 ET
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
2020-01-06 13:00 ET
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
2019-12-08 14:00 ET
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
2019-11-14 13:00 ET
Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
2019-11-06 14:00 ET
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
2019-11-05 12:00 ET
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
2019-10-28 12:00 ET
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-08-28 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences in September
2019-08-07 12:00 ET
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-08-06 12:00 ET
Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
2019-08-01 11:00 ET
Blueprint Medicines Reports Second Quarter 2019 Financial Results
2019-07-25 12:00 ET
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
2019-07-18 20:01 ET
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRa D842V Mutant GIST and Fourth-Line GIST
2019-06-14 12:45 ET
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-05-29 20:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences in June
2019-05-02 12:00 ET
Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
2019-04-02 20:01 ET
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
2019-03-29 00:40 ET
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
2019-03-05 13:01 ET
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
2019-02-26 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-19 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
2019-01-24 14:00 ET
Three Companies Using AI and Innovation to Lead Healthcare Sector

SEC forms

Show financial reports only

SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-05-01 20:19 ET
Blueprint Medicines reported for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-02-13 17:09 ET
Blueprint Medicines reported for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2024-10-30 16:27 ET
Blueprint Medicines reported for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-08-01 16:48 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Blueprint Medicines published news for 2024 q2
SEC form 10
2024-05-02 16:43 ET
Blueprint Medicines published news for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines reported for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Blueprint Medicines published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
Blueprint Medicines reported for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 10
2023-10-26 16:01 ET
Blueprint Medicines published news for 2023 q3
SEC form 8
2023-10-26 07:00 ET
Blueprint Medicines reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
Blueprint Medicines published news for 2023 q3
SEC form 10
2023-08-02 16:02 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-08-02 07:00 ET
Blueprint Medicines reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-06-30 06:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-27 16:01 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:07 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:05 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:52 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:48 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Blueprint Medicines reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Blueprint Medicines published news for 2022 q3
SEC form 8
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 8
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-02-17 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 8
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1